With all its management, organizational and personnel deficiencies Lilly could have a chance against Novo by going with oral or other delivery methods against injector delivery. Novo has its bag of problems too.
Bleak future because of the patent cliff. It will take at least several years to restore revenue. There will be some reorg and workforce cuts. Additional uncertainty will be changes in the healthcare system.
Stock seems to be very volatile going up or down a few %. This might be result of company instability and related poor management and bad strategy. But there could be another reason, managing to cause such stock price swings, so the founders, big investors and cronies can profit from these price swings. SEC may look closer at this manipulation.
Gilead has announced more than 100 person layoff coming, this time from the HQ location.
Streamlining ahead of a new administration, or as usual, a result of internal chaos and turmoil?
More layoffs would come in 2025.